ProCE Banner Activity

My Experience With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

Clinical Thought

An expert provides a review of the benefits of GLP-1 receptor agonists in patients with type 2 diabetes.

Released: January 03, 2023

Expiration: January 02, 2024

No longer available for credit.



Debbie Hinnen

Debbie Hinnen, APN, BC-ADM, CDCES, FAAN

Certified Diabetes Care and Education Specialist
Consultant, University of Colorado Health
Colorado Springs, Colorado

Provided by

ProCE Banner


This program is supported by an educational grant from

Novo Nordisk


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Debbie Hinnen APN, BC-ADM, CDCES: consultant/advisor/speaker: Intuity, Lilly/Boehringer Ingelheim, Novo, Sanofi.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose.